DV
Dividend Vision

SLN — Silence Therapeutics PLC

Silence Therapeutics PLC (SLN)

Total return is -29.6% over the past 5.9 years, 182.6 points behind SPY at 153.0%. Its deepest 1-year drawdown was 41.9%.

Silence Therapeutics plc is a biotechnology company developing novel siRNA-based therapies targeting hematology, cardiovascular, and rare diseases; its pipeline includes candidates such as Divesiran for polycythemia vera, Zerlasiran for cardiovascular disease, and programs in dyslipidemia, hypercholesterolemia, and obesity. The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biotechnology development with no current income component.

SLN key facts

Asset type
Stock
Asset class
Equity
Inception date
09/08/2020
Last close
$13.72
Market cap
$495,491,072
Average volume
824000.0
Beta
1.38
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.62